SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 and BMS ...

In recent days, CytomX Therapeutics drew attention after early-stage trial data for its Probody drug varsetatug maseatecan in metastatic colorectal cancer prompted upbeat reactions from multiple Wall ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--CytomX Therapeutics, the Probody™ therapeutics company, today announced the presentation of new data demonstrating preclinical proof of concept of the ...

SAN FRANCISCO – April 3, 2013 – CytomX Therapeutics, Inc., a biotechnology company developing a new generation of highly targeted antibody therapeutics, today announced that data highlighting the ...

- Collaboration to Utilize CytomX’s Novel Probody ® Technology Platform for CD3 Bispecific Targets - - CytomX to Receive $80 Million Upfront Payment and Ability to Exercise Option for U.S.

Bristol-Myers Squibb (BMS) is paying CytomX Therapeutics $200 million upfront to add up to eight new candidates to their existing Probody™ therapeutics collaboration. CytomX could potentially receive ...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of ...

Add Yahoo as a preferred source to see more of our stories on Google. JOHNSTOWN, Pa. – A nutrition and supplement store owner and a doctor have partnered to provide hormone replacement therapy in ...

Pfizer has terminated its five-year-old partnership with CytomX Therapeutics to use its Probody™ drug-development platform to develop and commercialize several antibody–drug conjugates (ADCs) for ...

Therapeutic drug monitoring of pazopanib: Using cost-neutral PK-guided interventions to optimize exposure. Prophylactic dihydropyrimidine dehydrogenase (DPYD), and reactive cytidine deaminase (CDA) ...